Dr. David Nierengarten

Wedbush

David Nierengarten is an analyst covering stocks in the biotechnology sector. His prior sellside research experience at Robert W. Baird & Co. covered biotechnology companies of all market capitalizations, with a focus on oncology and rare diseases. Nierengarten's prior early-stage venture capital investing experience helps him evaluate developmental-stage biotechnology companies that comprise his current major coverage focus. His experience on the other side of that equation, in a clinical-stage, venture-backed biotechnology company, provides him with additional insights into corporate operations. He received his bachelor's degree in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular and cell biology from the University of California Berkeley.

Recent Articles

New Blood Cancer Treatment Shows Continued Response 11/07/2024

The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report.

Mass. Biotech Shares Strong Q3 Results 10/29/2024

Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note.

Biotech Bolsters ADC Pipeline Through Atreca Asset Buy 12/26/2023

Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush.

Massachusetts Biotech Presents Catalysts Into 2024 11/08/2023

Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.

Firm To Present Trial Results Update at SITC Meeting 11/02/2023

Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.